A primary cause of disease progression in type 2 diabetes (T2D) is b cell dysfunction due to inflammatory stress and insulin resistance. However, preventing b cell exhaustion under diabetic conditions is a major therapeutic challenge. Here, we identify the vitamin D receptor (VDR) as a key modulator of inflammation and b cell survival. Alternative recognition of an acetylated lysine in VDR by bromodomain proteins BRD7 and BRD9 directs association to PBAF and BAF chromatin remodeling complexes, respectively. Mechanistically, ligand promotes VDR association with PBAF to effect genome-wide changes in chromatin accessibility and enhancer landscape, resulting in an anti-inflammatory response. Importantly, pharmacological inhibition of BRD9 promotes PBAF-VDR association to restore b cell function and ameliorate hyperglycemia in murine T2D models. These studies reveal an unrecognized VDR-dependent transcriptional program underpinning b cell survival and identifies the VDR:PBAF/BAF association as a potential therapeutic target for T2D.
In Brief
Modulation of a ligand-dependent switch between VDR-associated chromatin remodeling complexes enhances vitamin D response in b cells and curbs T2D progression.
INTRODUCTION
Already at epidemic proportions, the incidence of type 2 diabetes (T2D) is expected to continue largely unabated over the coming decades. Initiated by insulin resistance, b cell dysfunction is characterized by defective insulin secretion, endoplasmic reticulum (ER) stress, eventual b cell loss, and disease progression (Ashcroft and Rorsman, 2012; Donath et al., 2013; Halban et al., 2014; Weyer et al., 1999) . Although many therapeutic approaches are deployed to combat hyperglycemia, few (if any) treatments directly target b cell pathogenesis. Thus, long-term control of disease progression remains a persistent challenge.
Although the molecular underpinnings of obesity-induced b cell dysfunction are poorly understood, progress is being made. Increasing evidence links inflammation and specifically, the innate immune response of pancreatic islets to metabolic stress, to T2D progression (Donath and Shoelson, 2011; Ferná ndez-Real and Pickup, 2012; Imai et al., 2013) . In particular, inflammatory stress associated with increased interleukin 1b (IL1b) and other cytokines reduces insulin secretion and leads to b cell damage and loss of identity (Herder et al., 2015) . Blocking IL1b signaling by antagonists has shown modest b cell functional improvement, although the long term efficacy remains to be determined (Donath et al., 2013) .
While vitamin D is widely known for its role in bone homeostasis, interest in its anti-inflammatory potential continues to grow. In addition, epidemiological and human genetic studies linking vitamin D and the VDR to both type 1 and 2 diabetes , suggest a potential therapeutic role in diabetes (Baeke et al., 2010; Bouillon et al., 2008; Cantorna et al., 2004) . Indeed, vitamin D supplements are claimed to reverse many diabetic phenotypes in T1D rodent models by suppressing auto-immunity (Del Pino-Montes et al., 2004; Mathieu et al., 1994) . However, a therapeutic benefit in type 2 diabetic patients (or rodents) has yet to be established . Distinct from the general role in suppressing bone-derived innate and adaptive immune cells, the function of VDR in b cells remains unclear. Moreover, although VDR has been shown to be involved in anti-inflammatory responses in various contexts (Ding et al., 2013; Sherman et al., 2014) , how VDR responds to signals and initiates the downstream transcriptional cascade at the chromatin level remains largely a mystery.
Bromodomain-containing proteins 7 (BRD7) and 9 (BRD9) are closely related members of a diverse nuclear and cytoplasmic family of proteins that recognize acetylated lysines (Filippakopoulos and Knapp, 2014) . Interestingly, BRD9 has recently been identified as a core component of the SWI/SNF (BAF) complex, whereas BRD7 belongs to an alternative chromatin remodeling complex PBAF (Kadoch et al., 2013; Kaeser et al., 2008) . However, their specific roles within and beyond chromatin remodeling remain uncharacterized.
Here, we describe two opposing gene expression networks as upstream modulators of b cell stress and identify the balance between BAF-BRD9 and PBAF-BRD7 as a pivotal determinant of the VDR-driven anti-inflammatory and pro-survival response.
In the absence of ligand, BRD9 recruits the suppressive BAF complex to VDR. In a dual regulatory mechanism, inhibition of the VDR-BRD9 interaction in combination with ligand activation of VDR cooperate to dismiss the BAF-BRD9 complex and shift the balance to the activating PBAF-BRD7 complex to induce a coordinated transcriptional response. Notably, pharmacologically potentiated VDR signaling by a synthetic ligand in combination with a BRD9 inhibitor is able to partially restore b cell function and glucose homeostasis in various T2D mouse models. Our results reveal an unexpected epigenetic regulation of VDR transcriptional response via the post-translational modification of VDR and a balance between its bromodomain readers, and demonstrate the potential of enhanced VDR signaling in diabetes therapeutics.
RESULTS

VDR Is Required for b Cell Maintenance In Vitro
To explore the mechanisms regulating b cell survival and expansion, a genomic CRISPR knockout screen was performed in human induced pluripotent stem (iPS) cell-derived b-like cells (Yoshihara et al., 2016) . The incorporation of an inducible Cas9 expression system into b-like cells carrying a human insulin promoter-driven GFP reporter (INS-GFP) allowed genes essential for b-like cell maintenance to be identified (enrichment of single guide RNAs [sgRNAs] in GFP À compared to GFP + cells) ( Figure 1A ). Gene ontology analysis of the enriched genes reveals categories related to chromatin modification/ remodeling, cell cycle, and transcription ( Figure 1B) . Notably, this unbiased genomic screen identified VDR as one of the most enriched gene targets, with 6 of the 7 sgRNAs targeting VDR found only in the GFP À cells ( Figures 1C and 1D ). Consistent with a potential role for VDR in b cells, published datasets confirm pancreatic VDR expression in both b cells and a cells (Benner et al., 2014; DiGruccio et al., 2016; Xin et al., 2016) . Further interrogation of a single-cell transcriptional dataset revealed VDR to be one of the most highly expressed transcription factors in mouse islet cells, particularly in b cells (Figures S1A and S1B).
To explore the functional significance of VDR expression in b cells, iPS cell lines harboring inducible small hairpin RNA (shRNA) knockdowns of VDR were differentiated into b-like cells and then challenged with IL1b. Consistent with VDR playing a role in cell survival during stress, increased cytokine-induced cell death was seen in the VDR-depleted b-like cells ( Figure S2A ). Furthermore, in the rat b cell line INS1, the expressions of key b cell genes were reduced in cytokine and palmitic acid-treated cells upon VDR knockdown ( Figure S2B ). Moreover, whole body VDR knockout (KO) mice display increased islet staining for proinsulin, a marker of ER stress and b cell dysfunction, and an increased proinsulin:insulin ratio in the serum ( Figures 1E, 1F , S2C, and S2D) (Bouillon et al., 2008; Hasnain et al., 2014 Hasnain et al., , 2016 . While the reduced adiposity of the VDR KO mice limits their utility in evaluating the contribution of b cell-specific defects to altered glucose homeostasis (Narvaez et al., 2009) , the above findings combined with reduced levels of insulin and the survival factor MAFA in islets from VDR KO mice ( Figure S2E ) indicate that b cell function is compromised upon loss of VDR.
Given these findings, we next asked whether VDR activation can protect b cells against inflammatory damage. Isolated mouse islets were cultured with IL1b in the presence or absence of the synthetic VDR ligand, calcipotriol (Cal), and the transcriptomic changes determined by RNA sequencing (RNA-seq). Exposure to IL1b for 48 hr induced widespread transcriptional changes, with 704 and 718 genes up-and downregulated, respectively (p < 0.05, Figure S2F ). These transcriptional changes were largely maintained, with some even amplified, upon prolonged exposure (1,090 and 989 genes up-and downregulated after 96 hr, Figure S2F ). Notably, co-treatment with Cal protected islets from IL1b-induced damage, with more pronounced effects evident at the later time point ( Figures  S2F-S2J ). Gene ontology of the IL1b-suppressed genes whose expression was restored upon Cal treatment are mainly associated with b cell function, whereas the IL1b-induced genes repressed by Cal are associated with inflammation ( Figures  S2H and S2J ). These findings support the notion that VDR is able to protect against IL1b-induced b cell dysfunction, in part by counteracting the inflammatory response and maintaining b cell functionality.
VDR Shuttles between BRD9 and BRD7
To dissect the molecular underpinning of VDR function, we characterized the VDR interactome in human b-like cells. INS-GFP iPS cells with inducible HA-tagged VDR were differentiated into b-like cells and VDR expression induced to coincide with the peak expression of insulin, as measured by GFP expression. VDR was subsequently immunoprecipitated from cells grown in the presence or absence of Cal 24 hr after VDR induction, and associating proteins identified by mass spectrometry. Consistent with previous studies, multiple transcription elongation factors and components of the mediator and FACT complexes were found to co-immunoprecipitate with VDR ( Figure 2A ). In addition, novel VDR-interacting proteins were identified, most notably the bromodomain-containing factor 9 (BRD9), and its paralog, BRD7 (Figure 2A ). BRD9 was recently identified as a core component of the BAF complex, whereas BRD7 is found in the PBAF complex. Consistent with this, we showed that BRD9 selectively associates with the BAF but not the PBAF complex, as previously reported ( Figure S3A ) (Hodges et al., 2016) . Interestingly, BRD7 was also identified in our CRISPR screen (p = 0.002) (Figures 1B and S3B) .
To verify these novel VDR interactions, we first confirmed that endogenous BRD9 co-immunoprecipitates with HA-tagged VDR as well as endogenous VDR, and conversely, that HA-tagged VDR can be immunoprecipitated with Flag-tagged BRD9 in 293T cells (Figures 2B, 2C, and S3C) . Somewhat surprisingly, the strength of this interaction was markedly decreased in the presence of VDR ligand as measured by proteomic and western blot analyses . Furthermore, a selective inhibitor of the bromodomain of BRD9 (iBRD9) (Theodoulou et al., 2016) , also reduced the interaction between VDR and BRD9, suggesting that BRD9 directly binds to VDR via its bromodomain (Figures 2B and 2C) . Consistent with this, we show that the bromodomain of BRD9 is sufficient for the interaction with VDR (purified recombinant His-tagged VDR binds the GST-tagged bromodomain of BRD9) ( Figures 2D and S3F ). Because bromodomains bind acetylated lysines, we hypothesized that acetylation of VDR was required for the interaction. Indeed, mass spectrometry clearly showed the presence of an acetylated lysine in a VDR peptide containing lysine 91 (K91Ac) ( Figure S3G ). Interestingly, K91 is located in the T-box domain (legend continued on next page) (Lee et al., 1994; Quack et al., 1998) juxtaposed to the DNA-binding zinc fingers, a domain highly conserved in closely related nuclear receptors including RARa and PXR ( Figure 2E ). The structure of the VDR DNA-binding domain bound to direct repeat DNA elements (Orlov et al., 2012; Shaffer and Gewirth, 2002) reveals the side chain of K91 protruding away from the DNA double helix, suggesting it may serve as a docking site for the interaction with BRD9 ( Figure 2F ). To confirm the importance of K91Ac in the VDR:BRD9 interaction, we mutated K91 to alanine (K91A) or arginine (K91R). As predicted, mutating K91 significantly reduced the interaction with BRD9, as well as the total acetylation level of VDR ( Figures 2G and S3H) . Similarly, we confirmed that HA-tagged VDR was able to bind Flag-tagged BRD7 ( Figures 2H and S3I ). However, in contrast with BRD9, the interaction of VDR with BRD7 progressively increased in the presence of Cal and Cal+iBRD9, suggestive of competitive BRD9/BRD7 binding ( Figure 2H ). Indeed, we showed that VDR acetylation at the same site, K91, promoted the interaction with BRD7 ( Figure 2I ), supporting the competitive binding hypothesis. The notion of a ligand-induced shift in the association of VDR from BRD9 to BRD7 is supported by previous findings that revealed increased conformational flexibility in the DNA-binding domain and T box regions upon binding of 1,25(OH) 2 vitamin D (Zhang et al., 2011) ( Figure 2J ).
As the T-box region has been previously implicated in the interaction of nuclear receptors with PCAF (KAT2b) (Blanco et al., 1998) , we examined the interaction between VDR and PCAF. PCAF binding increased with Cal and/or iBRD9 treatment ( Figure 2K ), as seen for BRD7 but the reverse of that seen for BRD9 binding. As a lysine acetyltransferase, we explored whether PCAF directly acetylates VDR. VDR acetylation indeed increased when expressed together with PCAF, but not with the enzymatically dead PCAF D608A mutant (Jin et al., 2014) ( Figure 2L ). Taken together, the above findings suggest an unrecognized regulatory mechanism for VDR, whereby T-box acetylation partitions recruitment between BRD9 or BRD7, depending on the absence or presence of VDR ligand, respectively.
BRD9 Dissociation Promotes VDR-Mediated Transcription in b Cells
As BRD9 and BRD7 are components of the SWI/SNF (BAF) and PBAF complexes, respectively, they are in a position to mediate the alternative recruitment of VDR. To explore the idea of complex exchange, we added VDR ligand (Cal) to favor BRD7-PBAF association, iBRD9 to block re-association to BAF, as well as both compounds together. Proteomic analyses of INS1 cells expressing HA-tagged VDR confirmed the ligand-dependent association of VDR with its heterodimeric partner RXR as well as components of the basal transcriptional machinery (Figure 3A) . VDR association proteins common to the BAF and PBAF complexes similarly increased in the presence of Cal or iBRD9 (e.g., SMARCA1, SMARCA2, and SMARCA4) ( Figures 3A, 3B , and S4A-S4E). In addition, we find significantly enhanced interactions with key components of the PBAF complex including PBRM1 (BAF180) and ARID2 (but not BAF-specific components such as ARID1A and ARID1B) ( Figures 3A, 3B , and S4A-S4E). These findings suggest that the activation state of VDR K91Ac (i.e., ± Cal or iBRD9) is conditional, dependent on its association with the BAF or PBAF complexes.
Based on the above findings, we posited that BRD9 attenuates VDR activity. To explore the functional relevance of this molecular toggle in b cells, we determined the effects of Cal and iBRD9 upon IL1b-induced stress in INS1 cells (Hahn et al., 1997; Riachy et al., 2006) . Within 30 min of exposure, IL1b induced the expression of IkBa (aka Nfkbia), a key negative feedback early response gene (Verma et al., 1995) . Interestingly, this anti-inflammatory modulator was increased with both Cal and Cal+iBRD9 treatments ( Figure 3C ), with parallel changes seen at the protein level ( Figure 3D ). Furthermore, the induction of Nfkbia upon Cal treatment was largely abrogated in cells expressing the VDR dominant negative mutant (K91R) (Figure S4F) . Beyond an acute effect, the iBRD9-Cal combination led to sustained Nfkbia induction (>24 hr) ( Figure 3E ) portending a possible sustained anti-inflammatory effect (see below). Moreover, knockdown of the PBAF component PBRM1 or PCAF significantly compromised the activation of Nfkbia ( Figure 3F ). These findings support BRD9 as a regulator of unliganded VDR, whereby inhibition of BRD9 binding allows increased association of VDR with the PBAF complex and PCAF to prolong transcriptional activation.
Enhanced Activation of VDR Promotes a b Cell Stress Response
Transcriptional changes induced by the addition of Cal and iBRD9 were used to explore mechanistic transitions in cytokine-stressed b cells. 1 hr exposure of IL1b alone was sufficient to trigger rapid and widespread changes in INS1 cells, with 499 and 496 genes significantly induced and repressed, respectively (fold change >1.5) ( Figure 4A ). Notably, co-treatment with Cal+iBRD9 partially reversed the cytokine-induced inflammatory response, abrogating $25% of the IL1b-induced transcriptional changes (141 up-and 127 downregulated genes, Figures 4A and 4B). Within this regulated network, gene ontology (GO) analyses of these Cal+iBRD9 responsive genes identified b cell function ( Figure 4C ), along with cytokine response and nuclear factor kB (NF-kB) signaling ( Figure 4D ) in the IL1b-repressed and induced gene sets, respectively. Thus, the Cal+iBRD9 combination significantly protects against cytokine-induced transcriptional changes by reducing the proinflammatory response and preventing the loss in functionality of b cells. Our proteomics data indicated that inhibiting the interaction with BRD9 redirects VDR equilibrium toward the PBAF complex (Figures 3A and 3C) . Consistent with this, we show that Cal+iBRD9 treatment reduced ARID1B binding-a component of the BAF complex-and increased BAF180 binding-a hallmark of the PBAF complex-at multiple target gene promoters ( Figures S4G-S4L ). Given the established roles of the BAF and PBAF complexes in chromatin remodeling, we examined the impact of this VDR-shifted equilibrium on genome-wide chromatin accessibility. Notably, transposasebased sequencing (ATAC-seq) (Buenrostro et al., 2013) revealed chromatin remodeling upon Cal and iBRD9 treatment. IL1b-induced stress led to an overall reduction in chromatin accessibility in INS1 cells 1 hr after treatment ( Figure 4E ). In contrast, Cal and iBRD9 as single agents antagonized a large portion of these changes, resulting a significant increase (>4-fold) in chromatin accessibility at $4% (1,935 and 1,703 peaks) of all ATAC-seq peaks in IL1bÀtreated cells (Figures 4E and F) . The combined Cal+iBRD9 treatment further increased accessibility and resulted in global increases (>4-fold) at >3 times more peaks ($15%, 7,932 out of 51,397 peaks) (Figures 4E and 4F) . Motif analyses of Cal+ iBRD9-induced ATAC-seq peaks identified vitamin D response elements (VDREs) as the top-ranking motif together with CTCF ( Figure 4G ), implicating a direct role of VDR in counteracting the effects of IL1b. Indeed, chromatin accessibility was markedly increased at identified VDREs upon Cal+ iBRD9 treatment ( Figure 4H ). In particular, chromatin See also Figure S4 and Table S2. accessibility at Nfkbia and Nfkbiz was significantly increased upon Cal+iBRD9 treatment ( Figure 4I ), consistent with the sustained Nfkbia expression ( Figure 3I ). In addition, the reduction in chromatin accessibility induced by IL1b stress at key genes involved in b cell functionality including Cckar was reversed by Cal+iBRD9 treatment ( Figure 4I ). These findings support a model in which dissociating BRD9 from VDR by ligand or inhibitor results in selected chromatin accessibility by stabilizing ''hyper-open'' regions at VDR target genes.
Activation of VDR Reverses Cytokine-Induced Changes in Enhancer Landscape
To better understand how VDR shuttling between BAF and PBAF complexes impacts chromatin states, a genome-wide enhancer landscape was generated using H3K27Ac as a mark of active enhancers (Rada-Iglesias et al., 2011) . Short-term IL1b exposure (1 hr) significantly altered the enhancer landscape, with widespread decreases and increases in H3K27 acetylation ( Figures  5A and 5B, respectively). As was observed for chromatin accessibility ( Figure 4E ), Cal and iBRD9 as single agents were both able to partially reverse the impact of IL1b (Figures 5A and 5B). Examination of the sites where Cal+iBRD9 treatment increased H3K27 acetylation revealed VDRE as the most enriched motif ( Figure 5C ), implicating a direct role for VDR in reversing the IL1b-induced enhancer changes. Furthermore, an interrogation of the Cal+iBRD9-rescued gene set ( Figure 4B ) revealed that the VDRE-proximal decreases (at repressed genes) ( Figure 5D ) and increases (at activated genes) ( Figure 5E ) in H3K27 acetylation induced by IL1b were partially restored with Cal+iBRD9 treatment (Figures 5D-5F ).
Given the sustained hyper-activation of Nfkbia expression observed with the combined Cal+iBRD9 treatment ( Figure 3E ), we next determined the synergistic effect on epigenomic changes after a prolonged IL1b stress (6 hr). At this later time point, increased H3K27Ac with Cal+iBRD9 treatment was seen at 945 peaks compared to Cal alone, of which 149 (16%) contained VDREs ( Figure 5G ). The genes associated with these 
VDRE
+ peaks are mainly related to b cell function (e.g., Camk4) and anti-inflammatory responses (e.g., Nfkbia) (Figures 5H and 5I) . Concomitantly, Cal+iBRD9 treatment reduced H3K27Ac at 1,232 peaks, of which 130 (10.5%) contain VDREs ( Figure 5J) , with the VDRE + gene set mainly related to the inflammatory response ( Figures 5K and 5L ). Together, these data indicate a synergistic action of Cal+iBRD9 on H3K27Ac levels that affects both transcriptional activation and repression. The less pervasive changes in H3K27Ac levels compared to those in chromatin accessibility are consistent with alterations in enhancer elements being secondary to changes in chromatin accessibility. Combined with the marked changes in chromatin accessibility , these data identify a balance between PBAF-and BAF-modulated VDR transcription whereby VDR activation in combination with BRD9 inhibition shifts VDR toward the PBAF complex, resulting in reshaping of the enhancer landscape and antagonism of cytokine-induced transcriptomic changes.
VDR-PBAF Complex Reverses b Cell Dysfunction to Reduce Hyperglycemia
The improvements in markers of b cell survival and function with Cal+iBRD9 treatment suggest that this approach may have therapeutic utility. To explore this possibility, we investigated the benefits of Cal+iBRD9 treatment in a dietary stress mouse model. B6.BKS(D)-Leprdb/J (hereafter referred to as db/db (B6)) mice have markedly increased levels of cytokines that lead to both b cell dysfunction and insulin resistance (Chan et al., 2013) . To assess the potential for VDR-targeted therapies to ameliorate dietary-induced inflammatory stress, mice were injected with vehicle, Cal alone (60 mg/kg intraperitoneally [i.p.]), iBRD9 alone (10 mg/kg i.p.), or the combination (Cal: 60 mg/kg i.p. + iBRD9: 10 mg/kg i.p.) 3 times a week for 9 weeks. Vehicle-treated db/db (B6) mice developed pronounced hyperglycemia, with fasted blood glucose levels $400 mg/dL ( Figure 6A ). Cal and iBRD9 as single agents achieved modest improvements in blood glucose levels after 4-6 weeks treatment. Notably, mice receiving the Cal+iBRD9 combination showed a significant reduction in blood glucose after 4 weeks treatment, with the beneficial effects progressively increasing with treatment duration ( Figure 6A ). These improvements in glucose homeostasis were achieved without significant changes in body weight ( Figure 6B) , liver, or epididymal white adipose tissue (eWAT) weights, metabolic rate, or serum calcium level ( Figures S5A-S5E ). Intraperitoneal glucose tolerance tests (IPGTT) were performed to evaluate the functionality of the b cells independent of the incretin effect. While mice treated with Cal alone showed improved glucose clearance compared to vehicle-treated mice, more significant improvements were achieved with Cal+iBRD9 ( Figure 6C ), suggesting improved insulin secretion with the combination therapy. Consistent with this, random-fed serum insulin levels were significantly increased by Cal+iBRD9 treatment, and increased insulin secretion was observed during an intraperitoneal glucose challenge ( Figures 6D and 6E ). These findings indicate that activation of VDR combined with the dismissal of the BAF complex is able to improve b cell function and thereby glucose homeostasis in an inflammation-driven diabetes model. Mice lacking the leptin receptor on a BKS genetic background (C57BLKS-Leprdb, hereafter db/db [BKS]) develop a more severe diabetic phenotype than db/db(B6) mice (Garris and Garris, 2004) . Chronic hyperglycemia in db/db (BKS) progresses to b cell atrophy, hypoinsulinemia, and b cell failure, resembling the progression of patients with genetic defects in b cell function. In these genetically predisposed mice, treatment with Cal alone (60 mg/kg i.p. 3 times/week) provided only limited improvements in glucose management ( Figure 6F ). In contrast, 3 weeks cotreatment with Cal+iBRD9 was able to reduce the fasting blood glucose levels, and continued treatment maintained these levels for $10 weeks without any body weight changes (Figures 6F and S5F) . Consistent with improved glucose management, Cal+ iBRD9 treatment partially reversed the hallmark hypoinsulinemia associated with the db/db (BKS) model ( Figure 6G ).
Finally, we explored the therapeutic utility of targeting VDR in a b cell damage model, designed to mimic the severe b cell loss observed in the final stages of T2D patients. B6/J mice treated with low doses of streptozotocin (STZ) progressively lose glucose control. Interestingly, Cal and iBRD9 as single agents provided limited to no benefit in this b cell damage model. Notably, the combination Cal+iBRD9 treatment provided extended improvements in glucose control ( Figure 6H ) and increased glucose tolerance and serum insulin levels ( Figures  6I and S6D ). In combination, in vivo application of VDR ligand and iBRD9 results in enhanced b cell function and insulin secretion in each of the three mouse models representing different stages of T2D progression, strongly supporting the potential therapeutic value of this synergetic strategy.
Targeting the VDR-BRD9 Axis Rescues b Cell Dysfunction in Mouse and Human Islets
To understand how VDR activation improves glucose homeostasis in each of the three mouse models, we compared the molecular and structural changes induced in islets. The marked induction of Cyp24A1, a classic VDR target gene, confirmed VDR activation in islets as well as in the intestine of the Caltreated db/db (B6) mice ( Figure S6A ). In addition, Ins2 mRNA levels trended upward in Cal-treated islets, consistent with the increase seen in serum insulin levels ( Figures S6B and S6D ). Transcriptomic analysis revealed the upregulation of multiple key transcription factors including Nkx6-1 and Nr4a1 (Nur77) ( Figure 7A ), whose repression have been shown to correlate with b cell dysfunction (Guo et al., 2013; Talchai et al., 2012) . Furthermore, multiple cytokine and chemokine genes were downregulated, further supporting the conclusion that activation of VDR reduced the pro-inflammatory response in islets (Figure 7A) . Gene ontology of the upregulated genes identified pathways involved in b cell function including OXPHOS, secretion, and b cell proliferation enriched in the Cal-treated islets (Figure 7B ). In addition, we found reduced expression of gluconeogenesis genes including Pepck, Fbp1, and G6pase in the livers of Cal-treated mice, most likely linked to enhanced levels of serum insulin ( Figure S6C) . Thus, the benefits of VDR activation in the inflammation-driven db/db (B6) model are multifactorial, including reduced inflammation, improved b cell function, and decreased hepatic gluconeogenesis.
Distinct from diet-induced T2D models, b cell intrinsic defects in db/db (BKS) mice severely compromise b cell proliferation and are considered the major cause for the phenotype severity (Puff et al., 2011) . Notably, 12 weeks of Cal+iBRD9 treatment led to $70% increase in islet area in the pancreas, as well as a significant increase ($100%) in the size of individual islets in db/db (BKS) mice (Figures 7C-7E ). Consistent with these observations, the number of proliferating cells measured by Ki67 labeling more than doubled after Cal+iBRD9 treatment ( Figures 7F and 7G) . Moreover, based on immunologic stains, intracellular insulin levels were also rescued by Cal or Cal+iBRD9 treatment (Figure 7H) , suggesting that dysfunction within the b cell (Guo et al., 2013 ) is reversed upon VDR activation.
As a common model of phase III or end stage diabetes, lowdose STZ treatment induces islet loss and a cell expansion (Li et al., 2000) . Cal+iBRD9 treatment was protective against progressive b cell death, with increased insulin and decreased glucagon staining ( Figure 7I ) seen after 7 weeks of treatment (quantified in Figure 7J ). These changes were accompanied by Data reported as mean ± SEM, *p < 0.05. See also Figure S5 and Table S3 . 
(legend continued on next page)
an increase in the level of NKX6-1, a marker for b cell function ( Figure S6E ), further supporting that the b cell dysfunction caused by multiple layers of stress is ameliorated upon enhanced VDR activation. The above findings indicate that Cal+iBRD9 treatment improves glucose homeostasis in multiple diabetic mouse models through the reversal of b cell dysfunction and increased insulin secretion.
In addition to inflammation, ER stress, and IAPP amyloid deposition, lipo-and glucotoxicity all contribute to islet dysfunction in human T2D patients (Mukherjee and Soto, 2017; Papa, 2012) . To test whether vitamin D signaling can modulate the damage attributed to additional stressor, we treated islets from aged (15 months) transgenic mice carrying a copy of human islet amyloid polypeptide driven by rat insulin II promoter (Janson et al., 1996) with Cal or Cal+iBRD9 for 72 hr ex vivo. Multiple inflammatory and stress markers were reduced upon Cal or Cal+iBRD9 treatment ( Figure S6F ). In addition, thapsigargin or tunicamycin-induced ER stress in INS1 cells was attenuated by Cal treatment ( Figure S6G ). Finally, ER stress markers Calnexin and PERK were reduced in db/db (BKS) mice treated with Cal or Cal+iBRD9 ( Figure S6H ), suggesting that VDR activation can reduce ER stress in highly dysfunctional b cells in vivo.
While the significant improvements seen in the diabetic models are consistent with the effects observed in b cell lines upon Cal+iBRD9 treatment, efficacy in related tissues such as macrophages or the intestines, or off target effects cannot be excluded . In support of the specificity of iBRD9, structurally unrelated BRD9 inhibitors Martin et al., 2016) induced similar anti-inflammatory effects on NF-kB signaling ( Figure S6I ). In addition, the maximum plasma iBRD9 concentration ($750 nM) ( Figure S6J ) is sufficient to activate BRD9 (IC 50 = 50 nM) while sparing other bromodomain members such as BRD4 (IC 50 = 5 mM) (Theodoulou et al., 2016) . Collectively, these data support that the therapeutic efficacy of iBRD9 in vivo is on-target.
As islet allogenic transplants are a medium-term therapy for select patients, we explored the ability of VDR activation to protect isolated human islets. Healthy human islets were challenged with an inflammatory stress (Arnush et al., 1998) (IL1b+interferon g [IFNg] for 24 hr) with or without activation of VDR. Transmission electron microscopy confirmed that IL1b and IFNg caused severe islet damage including loss of dense insulin granules and dilation of the ER, as previously reported (Ravelli et al., 2013; Song et al., 2008) (Figure 7K , upper and lower insets, respectively). Activation of VDR alone or in combination with iBRD9 rescued the damage caused by IL1b and IFNg, most notably at the level of the insulin granules ( Figure 7K , upper insets, bottom panels) and ER morphology ( Figure 7K , lower insets, bottom panel). Additionally, Cal increased survival and insulin secretion capacity in long term ex vivo human islet cultures ( Figures S7A and S7B ). While these findings will require further validation in additional human samples, they support the conclusion from the mouse models that enhanced vitamin D signaling has significant beneficial effects on islets during cytokine stress.
DISCUSSION
Here, we identify VDR as a critical factor in b cell survival and function. Initially identified in an unbiased CRISPR knockout screen, genetic loss-of-function and ex vivo gain-of-function studies support a protective role for VDR in b cells and the modulation of islet stress. In exploring the regulatory mechanisms of VDR-driven transcriptional action, we demonstrate the shuttling of VDR between competing chromatin remodeling complexes ( Figure 7L ). Specifically, we describe a novel acetylated lysine in VDR that facilitates its recognition by the highly related bromodomain reader proteins, BRD9 and BRD7, respective components of the BAF and PBAF complexes. We show that VDR shuttles between BAF and PBAF complexes in a ligand-dependent fashion. Furthermore, we show that a highly selective BRD9 inhibitor, iBRD9, cooperates with VDR ligand to favor PBAF complex binding and significantly potentiates VDR signaling. Mechanistically, binding of the PBAF complex enhances chromatin accessibility at consensus VDR binding elements to modulate the expression of key inflammatory response genes including the inhibitor of NF-kB, Nfkbia.
Despite many shared components, the BAF and PBAF complexes are distinct assemblies with functional differences (Hodges et al., 2016) . While the PBAF complex has been shown to be a superior transcriptional activator for nuclear receptors compared to the BAF complex in vitro (Lemon et al., 2001; Rafati et al., 2011) , the ability of these two complexes to mediate ligand-dependent signaling was not previously known. Here we describe a novel mechanism in which acetylation at K91 in VDR is recognized by the BRD7/9 subfamily of bromodomain proteins that facilitate the alternative association of the PBAF and BAF complexes in a ligand-dependent fashion. Fortuitously, the switching of VDR's partner from BAF-BRD9 to PBAF-BRD7 can also be pharmacologically manipulated by targeting the ''reader'' of VDR acetylation, thereby providing an additional level of nuclear receptor signaling regulation. Table S1 .
Pro-inflammatory cytokines such as IL1b and tumor necrosis factor alpha (TNF-a) are detrimental to b cell and islet function (Nackiewicz et al., 2014) and are the ongoing targets of multiple clinical trials (Imai et al., 2013) . However, use of selective inhibitors of inflammation to treat T2D have produced only modest improvements (Donath, 2016) . In contrast, exploiting VDR as a negative modulator of NFkB signaling in b cells is highly effective, and we show the combination of a VDR activator with a BRD9 inhibitor results in remarkably prolonged suppression of the damaging effects of inflammatory insults.
While multiple therapies aimed at improving b cell function are in the clinic or under development, chronic stress-induced damage to b cells continues to pose a serious challenge for long-term therapeutic efficacy (Zhou et al., 2016) . By focusing on the VDR shuttle between BAF and PBAF complexes, we uncover an unusual therapeutic strategy to suppress inflammation via sustained receptor activation in b cells. This strategy demonstrates the power of genomic reprogramming, tackling the problem at the genome-wide level. As this is a natural way in which b cells normally limit chronic inflammation, exploiting the power of the VDR, its acetylation, and the safety of its ligands offer a very different approach in the treatment of T2D.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
Biological Samples
Human islets
See Table S1 N/A Chemicals, Peptides, and Recombinant Proteins Calcipotriol Tocris Cat#2700 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by Lead Contact, Ronald M. Evans (evans@salk.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Differentiation of hiPSC to human b-like cells As previously described (Yoshihara et al., 2016) , INS-GFP hiPSCs (derived from HUVECs) were cultured to 90% confluency in complete mTeSR Media, at which time the media was changed to 100 ng/ml Activin (R&D Systems, 338-AC), 25 ng/ml Wnt3a (R&D Systems, 5036-WN) in differentiation media (800 mL DMEM/F12, 13.28 g BSA, 10 mL Glutamax, 560 mg NaHCO3, 330 mg thiamine, 100 mg reduced glutathione, 3300 mg vitamin C, 14 mg selenium, 10 mL NEAA, 2 mL trace element B, 1 mL trace element C, 7 mL b-ME, 2 mL DLC, 2 mL GABA, 2 mL LiCl, 129.7 mg pipecolic acid, insulin 2 mg up to 1,000 ml) for 2 days and then 100 ng/ml activin in differentiation media for another 2 days. Subsequently, media was replaced with differentiation media with 1 mM dorsomorphin (Biovision, 1656-5), 2 mM retinoic acid (Sigma, R2625-1G), 10 mM SB431542 (Sigma, S4317-5MG), and 1% B27 supplement (GIBCO, 17504-044) for 7 days. Media was then replaced with 10 mM Forskolin (Sigma, F6886-25MG), 10 mM dexamethasone (Sigma, D4902-100MG), 10 mM Alk5 inhibitor II (Calbiochem, 616452 or Enzo, ALX-270-445), 10 mM nicotinamide (Sigma, 72340-100G), 1uM 3,3 0 ,5-Triiodo-L-thyronine sodium salt (T3), and 1% B27 supplement 10 days. At days 21, the expression of INS-GFP were confirmed regularly by fluorescence microscopy. Stem cell culture were supported by the Stem Cell Core Facility of the Salk Institute with funding from the Helmsley Charitable Trust (K. Diffenderfer).
Mice
Animals were maintained in a specific pathogen-free animal facility on a 12-hr light-dark cycle at an ambient temperature of 23 C. Water and food were provided ad lib. All animal experiments used age-matched male mice. VDR KO and control litter mice were maintained on a VDR KO rescue diet containing 21% calcium, 0.67% phosphorus, and 20% lactose supplemented with 4.4 U vitamin D per gram diet. All procedures involving animals were performed in accordance with protocols approved by the IACUC and Animal Resources Department of the Salk Institute for Biological Studies.
T2D animal model treatment
For db/db (B6), mice were grouped based on glucose levels at age of 5 weeks. Treatments were started from 6 weeks of age and animals were treated with vehicle (30% 2-Hydroxypropyl-b Cyclodextrin, Sigma, H-107) or drugs 3 times a week. Cal (Tocris, 60ug/kg) and iBRD9 (R&D, 10mg/kg) were dissolved in 30% b-cyclodextran and injected intraperitoneally 3 times a week. For db/db (BKS), treatment started from the age of 10 weeks. Cal (Tocris, 30ug/kg) and iBRD9 (R&D, 5mg/kg) were dissolved in 30% b-cyclodextran and injected intraperitoneally 3 times a week.
Low-dose STZ induction 8 week old C57Bl6 male mice were injected intraperitoneally with streptozotocin (Sigma, S0130) at the dose of 50mg/kg every day for 5 consecutive days. Blood glucose was measured 1 week after the final injection and mice were separated into different treatment groups to ensure all groups have similar starting glucose levels.
Isolation of Pancreatic Islets
Mouse pancreatic islets were isolated as previously described (Yoshihara et al., 2010) with slight modification. Briefly, 0.5 mg/ml collagenase P (Roche REF11213873001, diluted in HBSS buffer, GIBCO, 14170-112) was injected through the common bile duct, and the perfused pancreas dissected and incubated at 37 C for 21 min. Digested exocrine cells and intact islets were separated via centrifugation (900 3 g for 15 min) over Histopaque-1077 (Sigma, H8889), and intact islets were manually selected. Human islets were provided by the Integrated Islets Distribution Program under an approved protocol (Table S1 ).
METHOD DETAILS
CRISPR screening ''Drop off'' genome-wide CRISPR screening was performed using a protocol similar to that described previously . We transduced a Tet-ON inducible rtTA and subsequently a genomic lentiviral sgRNA library into an INS (human insulin promoter)-GFP iPS cell lines as reported in previous work (Yoshihara et al., 2016) . By selecting with 3 different markers (puromycin for rtTA, blasticidin for sgRNA library and neomycin for insulin-GFP), we obtained iPS cell lines that contain both vectors and maintained at least 5X10 7 cells for every passage to guarantee the coverage of library. Cells were subjected to standard differentiation protocols and the rtTA was induced after 2 weeks of differentiation, concurrent to expression of INS-GFP. Doxycycline (1 mg/ml) was then added for 1 week. Subsequently, the cells were FACS-sorted by GFP expression and both GFP+ and GFP-cells from the same batch were collected, extracted for genomic DNA and libraries were prepared for high throughput sequencing. The sgRNA sequences were amplified with primers described previously and sequenced by HiSeq 2500. The sequences were aligned and analyzed by MAGeCK (https://sourceforge.net/p/mageck/wiki/Home/). FACS was supported by the Flow Cytometry Core Facility of the Salk Institute with funding from NIH-NCI CCSG: P30 014195 (C. O'Connor).
RNA-Seq library generation
Total RNA was isolated from tissue or cell pellets using the RNA mini kit (QIAGEN). Sequencing libraries were prepared from 100-500ng total RNA using the TruSeq RNA Sample Preparation Kit v2 (Illumina) according to the manufacturer's protocol. Briefly, mRNA was purified, fragmented, and used for first-, then second-strand cDNA synthesis followed by adenylation of 3 0 ends. Samples were ligated to unique adapters and subjected to PCR amplification. Libraries were then validated using the 2100 BioAnalyzer (Agilent), normalized, and pooled for sequencing. RNA-Seq libraries prepared from two biological replicates for each experimental condition were sequenced on the Illumina HiSeq 2500 using bar-coded multiplexing and a 100bp read length.
High-throughput sequencing and analysis
Image analysis and base calling were performed with Illumina CASAVA-1.8.2. This yielded a median of 29.9M usable reads per sample. Short read sequences were mapped to a UCSC mm10 reference sequence using the RNA-seq aligner STAR. Known splice junctions from mm10 were supplied to the aligner and de novo junction discovery was also permitted. Differential gene expression analysis, statistical testing and annotation were performed using Cuffdiff 2. Transcript expression was calculated as gene-level relative abundance in fragments per kilobase of exon model per million mapped fragments and employed correction for transcript abundance bias. RNA-Seq results for genes of interest were also explored visually using the UCSC Genome Browser.
Gene Expression Analysis by qPCR
Samples were run in triplicate and expression was normalized to the levels of the housekeeping controls Rplp0 (36b4) for human and mouse. Primers used are listed in Table S2 . Samples were analyzed by qPCR, using SYBR Green dye (Bio-rad). Statistical comparisons were made using Student's t test. Error bars are mean ± SEM.
Metabolic Cage Analyses
Metabolic cage analyses were conducted with a Comprehensive Lab Animal Monitoring System (Columbus Instruments). CO2 production, O2 consumption, RER, and ambulatory counts by x-peak were determined for 3 consecutive days and nights, with at least 24 hr adaptation before data recording.
Histology (H&E staining, Immunohistochemistry and immunofluorescence) H&E staining was performed by Pacific Pathology (San Diego) and UCSD pathology core.
For immunohistochemistry, FFPE tissue sections were FFPE tissues sections were deparrafinized and antigen retrieval were performed using Vector Antigen Unmasking buffer (H3301). VectaStain ABC kit and ImmPACT DAB substrate (Vector Lab) were used to develop signal. Antibody used: Pro-insulin (R&D, MAB13361, 1:100).
For immunofluorescence staining, FFPE tissues sections were deparrafinized and antigen retrieval were performed using Vector Antigen Unmasking buffer (H3301). Antibody used: insulin (Abcam, ab7842, 1:100), MAFA (Novus, NB400-137, 1:50), NKX6-1 (Cell Signaling, 54551, 1:100), Glucagon (abcam, ab82270, 1:100). DAPI-containing mounting media (VECTASHIELD mounting medium for fluorescence) was used for nuclear staining. Immunostaining was visualized by ZEISS 780 confocal microscopy analysis.
Immunoprecipitation Briefly, cells are lysed using ice-cold lysis buffer (HEPES 20mM pH8, EDTA 0.2mM, NaCl 0.3 mM, NP40 0.5%, 15% glycerol) for 15 min, and after centrifuge the supernatant was collected. For HA-or Flag-tagged protein, immunoprecipitations were performed using HA-magnetic beads (Pierce, PI88836), or Flag-magnetic beads (Sigma, M8823) for 1.5 hr at 4C. For other immunoprecipitations, primary antibodies were incubated with lysate for 2 hr followed by Protein A magnetic beads (Life Technologies, 10001D). After 3 washes with wash buffer (HEPES 10mM pH8, EDTA 0.2 mM, NaCl 0.3 mM, NP40 0.1%, 15% glycerol), the beads were boiled with NuPage LDS sample buffer and the lysate were stored at À20 C. For mass-spec samples detecting VDR acetylation, HA-tagged VDR was transfected together with a plasmid expressing p300 and HDAC inhibitor TSA (1 mM) were added in all buffers. For immunoprecipitation with endogenous VDR, antibody was first crosslinked with dynabeads using Dynabeads immunoprecipitation kit (Life technologies, 14321D).
Mass-spec
Samples were precipitated by methanol/ chloroform. Dried pellets were dissolved in 8 M urea/100 mM TEAB, pH 8.5. Proteins were reduced with 5 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP, Sigma-Aldrich) and alkylated with 10 mM chloroacetamide (Sigma-Aldrich). Proteins were digested overnight at 37 C in 2 M urea/100 mM TEAB, pH 8.5, with trypsin (Promega). Digestion was quenched with formic acid, 5% final concentration.
The digested samples were analyzed on a Fusion Orbitrap tribrid mass spectrometer (Thermo). The digest was injected directly onto a 30cm, 75um ID column packed with BEH 1.7um C18 resin (Waters). Samples were separated at a flow rate of 200nl/min on a nLC 1000 (Thermo). Buffer A and B were 0.1% formic acid in water and acetonitrile, respectively. A gradient of 1%-30%B over 90min, an increase to 40%B over 30min, an increase to 90%B over another 10min and held at 90%B for a final 10min of washing was used for 140min total run time. Column was re-equilibrated with 20ul of buffer A prior to the injection of sample. Peptides were eluted directly from the tip of the column and nanosprayed directly into the mass spectrometer by application of 2.5kV voltage at the back of the column. The Orbitrap Fusion was operated in a data dependent mode. Full MS1 scans were collected in the Orbitrap at 120K resolution with a mass range of 400 to 1600 m/z and an AGC target of 5e5. The cycle time was set to 3sec, and within this 3sec the most abundant ions per scan were selected for CID MS/MS in the ion trap with an AGC target of 1e4 and minimum intensity of 5000. Maximum fill times were set to 50ms and 100ms for MS and MS/MS scans respectively. Quadrupole isolation at 1.6 m/z was used, monoisotopic precursor selection was enabled and dynamic exclusion was used with exclusion duration of 5 s.
Protein and peptide identification were done with Integrated Proteomics Pipeline -IP2 (Integrated Proteomics Applications). Tandem mass spectra were extracted from raw files using RawConverter (He et al., 2015) and searched with ProLuCID (Xu et al., 2015) against rat UniProt database. The search space included all fully-tryptic and half-tryptic peptide candidates. Carbamidomethylation on cysteine was considered as a static modification. Acetylation (42.010565) was considered as a differential modification on Lysine and the N terminus. Data was searched with 50 ppm precursor ion tolerance and 600 ppm fragment ion tolerance. Data was filtered to 10 ppm precursor ion tolerance post search. Identified proteins were filtered using DTASelect (Tabb et al., 2002) and utilizing a target-decoy database search strategy to control the false discovery rate to 1% at the protein level. Mass-spec was performed by Mass Spectrometry Core of the Salk Institute with funding from NIH-NCI CCSG: P30 014195 and the Helmsley Center for Genomic Medicine (J. Moresco, J. Diedrich and W. Low).
siRNA knockdown assay INS1 cells were cultured at 37 C in 5% CO2 in air in RPMI-1640 (Sigma Aldrich) supplemented with 10% (v/v) fetal bovine serum, 1% (v/v) Antibiotic-Antimycotic (GIBCO) 10 mM HEPES, 2 mM glutamax, 1 mM sodium pyruvate, and 50 mM b-mercaptoethanol (RPMI for INS1 medium). INS1 cells were transfected with Lipofectamine RNAiMAX (Invitrogen) for 24 hr, and cytokines were added for 24 hr or 1 hour.
Intraperitoneal Glucose or Insulin Tolerance Tests
Intraperitoneal GTTs were performed on overnight fasted mice. Blood glucose values were assessed before and at 0, 15, 30, 60, and 120 min after i.p. administration of 0.5 g/kg of glucose. Serum insulin levels were assessed before and at 0, 15, and 60 min after the i.p. administration of glucose using a rat/mouse Insulin ELISA kit (Millipore). IP-ITT assays were performed on mice after a 6 hr fast with an injection of 2 U/kg of insulin (Humalin R, Eli Lilly).
shRNA knockdown shRNA constructs for human VDR, as well as control shRNA, were purchased from Transomics. Lentiviral shRNA were produced in 293T cells and polybrene (6 mg/ml) was used in transduction. Puromycin selection performed for 1 week at concentration of 1ug/ml. were as follows: spray voltage 3.5 kV, ion transfer tube temperature of 325 C, and a vaporizer temperature of 275 C. Multiple reaction monitoring transitions for target compound and internal standard are shown in (Table S3) .
QUANTIFICATION AND STATISTICAL ANALYSES
All statistical details of experiments are included in the Figure legends or specific Methods section. Band intensities were quantified with Fiji and normalized with internal control.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data reported in this paper is NCBI SRA: SRP103617. The accession number for the ChIPseq and ATAC-seq data reported in this paper is SRA: SRP103615.
